# POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC

> **NCT02845908** · PHASE2 · COMPLETED · sponsor: **Fujian Cancer Hospital** · enrollment: 90 (actual)

## Conditions studied

- Malignant Neoplasm of Stomach Stage IV

## Interventions

- **DRUG:** POF
- **DRUG:** FOLFOX
- **DRUG:** FOLFOX plus PAC(ip)

## Key facts

- **NCT ID:** NCT02845908
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-05
- **Final completion:** 2020-05
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02845908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02845908, "POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02845908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*